Evidence map›Paper›PMID 25018908›Full record

ReviewKidney international supplements2011

Stem cell therapy for diabetes mellitus.

Júlio C Voltarelli, Carlos E B Couri, Maria C Oliveira, Daniela A Moraes, Ana B P L Stracieri, Fabiano Pieroni, George M N Barros, Kelen C R Malmegrim, Belinda P Simões, Angela M O Leal and 1 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Kidney international supplements, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Júlio C VoltarelliDepartment of Clinical Medicine, Ribeirão Preto School of Medicine, University of São Paulo , São Paulo, Brazil.
Carlos E B CouriDepartment of Clinical Medicine, Ribeirão Preto School of Medicine, University of São Paulo , São Paulo, Brazil.
Maria C OliveiraDepartment of Clinical Medicine, Ribeirão Preto School of Medicine, University of São Paulo , São Paulo, Brazil.
Daniela A MoraesDepartment of Clinical Medicine, Ribeirão Preto School of Medicine, University of São Paulo , São Paulo, Brazil.
Ana B P L StracieriDepartment of Clinical Medicine, Ribeirão Preto School of Medicine, University of São Paulo , São Paulo, Brazil.
Fabiano PieroniDepartment of Clinical Medicine, Ribeirão Preto School of Medicine, University of São Paulo , São Paulo, Brazil.
George M N BarrosDepartment of Clinical Medicine, Ribeirão Preto School of Medicine, University of São Paulo , São Paulo, Brazil.
Kelen C R MalmegrimDepartment of Clinical Medicine, Ribeirão Preto School of Medicine, University of São Paulo , São Paulo, Brazil.
Belinda P SimõesDepartment of Clinical Medicine, Ribeirão Preto School of Medicine, University of São Paulo , São Paulo, Brazil.
Angela M O LealDepartment of Medicine, Federal University of São Carlos , São Carlos, Brazil.
Milton C FossDepartment of Clinical Medicine, Ribeirão Preto School of Medicine, University of São Paulo , São Paulo, Brazil.
Universidade de São Paulo · BRUniversidade Federal de São Carlos · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this review, we present (1) a brief discussion of hematopoietic stem cell transplantation (HSCT) for severe and refractory autoimmune diseases (AIDs) from its beginning in 1996 through recently initiated prospective randomized clinical trials; (2) an update (up to July 2009) of clinical and laboratory outcomes of 23 patients with newly diagnosed type 1 diabetes mellitus (T1DM), who underwent autologous HSCT at the Bone Marrow Transplantation Unit of the Ribeirão Preto Medical School, University of São Paulo, Brazil; (3) a discussion of possible mechanisms of action of HSCT in AIDs, including preliminary laboratory data obtained from our patients; and (4) a discussion of future perspectives of stem cell therapy for T1DM and type 2 DM, including the use of stem cell sources other than adult bone marrow and the combination of cell therapy with regenerative compounds.

Indexed as

diabetes mellitushematopoietic stem cellstem cell therapy

Identifiers

PMID25018908
PMCPMC4089753
OpenAlexW2103733745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.